Expertise

robert blank_headshotbw

Robert Blank

Managing Consultant

EVERSANA

Robert Blank

Robert Blank is a managing consultant at EVERSANA, working extensively in revenue management software solutions for the pharmaceutical and medical device industries. His expertise includes Medicaid and Managed Care rebates, chargebacks, and membership management. He has developed custom client solutions around value based contracting, formulary validation, discount reallocation, and the 340B Drug Pricing Program. In his speaking engagements and published articles, Robert focuses on outlining industry trends and the impacts of legislation upon commercial operations.

Expertise:

Revenue Management

Articles by Robert Blank

white paper-insights
340B Drug Pricing: Challenges and Best Practices

Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has  also become notoriously difficult to manage for the more than 600 pharmaceutical companies enrolled. Data validity, crossover between lines of business, and conflicting regulations each […]

Streamline Chargeback and Channel Operations

Robert Blank, Managing Consultant at EVERSANA, moderated a panel with industry experts from Sanofi, Zydus, and UCB at CBI’s 15th Annual Commercial Contract and Chargeback Excellence.  The topic: “Process Improvement in Contract Administration and Management — Streamlining Chargeback Operations, GPO Rosters and Channel Operations.” If you missed this presentation, download Robert’s white paper on the […]

no-image
Membership Management Challenges and Best Practices

In the pharmaceutical industry, access to pricing is primarily driven by membership.Institutions like hospitals, clinics, and pharmacies sign up as members of a Group Purchasing Organization (GPO) to be eligible to purchase products at a discounted rate. In turn, the GPO leverages its collective purchasing power with the pharmaceutical manufacturers to secure a lower price […]

no-image
Pharmaceutical Contracting from Volume to Value

Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies, regulations, organization structures, and systems have held back the tide, industry analysts agree that the tipping point is being […]

white paper-insights
Medicaid Drug Classification: Civil Monetary Penalties

On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective immediately, this law enables the Center for Medicare and Medicaid Services (CMS) to impose civil monetary penalties on any […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.